Compare Las Vegas Sands Corp. (LVS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs GeneDx Holdings Corp — how do they compare? Las Vegas Sands Corp. trades at $36.2 (market cap $23.38B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Las Vegas Sands Corp. is far larger — about 11.6× GeneDx Holdings Corp's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and GeneDx Holdings Corp for 19 Days on average.
| LVS | WGS | |
|---|---|---|
Market Cap | $23.38B | $2.02B |
Volume | 6,994,661 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $167.51 |
52-Week Low | $35.81 | $34.51 |
Typical Hold Time | 72 Days | 19 Days |
Enterprise Value | $35.27B | $2.05B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.17, up 1.01% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 12.59% net margin and 134.29% ROE, supported by $13.02B in 2025 revenue. Analysts are bullish with a $59.78 consensus target, but the stock faces headwinds from high debt levels and a recent Q2 2026 earnings miss.
The outlook for LVS is mixed; solid fundamentals and analyst support suggest upside, but technical weakness and leverage risks warrant caution. Investment opportunity lies in valuation discount versus peers, while risks include debt servicing and Macao regulatory exposure.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
